Eli Lilly & Co. announces collaborations with Dana-Farber and Sarah Cannon Research Institute

As Trump’s second term nears, Republican support for NIH is at a low point
By stonewalling GOP in the House, Biden’s HHS officials eroded bipartisan support for biomedical research

The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.

November 22, 2024

Vol.50 No.44

By Paul Goldberg

Patient navigation benefits health systems, improves care
Initial data presented at the White House come a year after CMS payment began

One year after the Centers for Medicare & Medicaid Services made the decision to pay for patient navigation services, data from early adopters show that navigation services are leading to better outcomes, significant cost savings for healthcare systems, and mitigation of health inequities.

Cedars-Sinai spearheads first national certification program for COE staff at cancer centers

The NCI Cancer Center Support Grant requires community outreach and engagement, but the design and implementation of COE programs, as well as staff training, are largely left to individual institutions.

November 22, 2024

Vol.50 No.44

By McKenzie Prillaman

Clinical Trials & Tribulations

Menin inhibitors emerge as new treatment for advanced AML

The world of cancer treatments continues to evolve, and for those diagnosed with blood cancers, a new option can be found in menin inhibitors—the latest form of targeted therapy in advanced acute leukemia.

November 22, 2024

Vol.50 No.44

By Ghayas Issa

In the Archives

Larry Einhorn reflects on his pioneering work on platinum-based chemotherapy at the AACI/CCAF annual meeting

When Larry Einhorn was a young physician in the early 1970s, actinomycin-D was the standard drug used to treat testicular cancer. It was—and still is—the most common carcinoma in young men ages 15-35.

November 22, 2024

Vol.50 No.44

By McKenzie Prillaman

In Brief

Krish Patel joins Sarah Cannon as director of lymphoma research

Krish Patel was appointed director of lymphoma research at Sarah Cannon Research Institute.

November 22, 2024

Vol.50 No.44

Eli Lilly & Co. announces collaborations with Dana-Farber and Sarah Cannon Research Institute

YOU MAY BE INTERESTED IN

As Trump’s second term nears, Republican support for NIH is at a low point
By stonewalling GOP in the House, Biden’s HHS officials eroded bipartisan support for biomedical research

Patient navigation benefits health systems, improves care
Initial data presented at the White House come a year after CMS payment began

Cedars-Sinai spearheads first national certification program for COE staff at cancer centers

Menin inhibitors emerge as new treatment for advanced AML

Larry Einhorn reflects on his pioneering work on platinum-based chemotherapy at the AACI/CCAF annual meeting

Krish Patel joins Sarah Cannon as director of lymphoma research

Renew today!

Subscriber content

Never miss an issue!

Login

Eli Lilly & Co. announces collaborations with Dana-Farber and Sarah Cannon Research Institute

YOU MAY BE INTERESTED IN

As Trump’s second term nears, Republican support for NIH is at a low pointBy stonewalling GOP in the House, Biden’s HHS officials eroded bipartisan support for biomedical research

Patient navigation benefits health systems, improves careInitial data presented at the White House come a year after CMS payment began

Cedars-Sinai spearheads first national certification program for COE staff at cancer centers

Menin inhibitors emerge as new treatment for advanced AML

Larry Einhorn reflects on his pioneering work on platinum-based chemotherapy at the AACI/CCAF annual meeting

Krish Patel joins Sarah Cannon as director of lymphoma research

Never miss an issue!

Login

As Trump’s second term nears, Republican support for NIH is at a low point
By stonewalling GOP in the House, Biden’s HHS officials eroded bipartisan support for biomedical research

Patient navigation benefits health systems, improves care
Initial data presented at the White House come a year after CMS payment began